+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new prognostic model for FIGO stage 1 epithelial ovarian cancer

A new prognostic model for FIGO stage 1 epithelial ovarian cancer

Gynecologic Oncology 104(3): 607-611

No consensus exists which patients with surgical stage 1 epithelial ovarian should receive postoperative chemotherapy. The purpose of this study was to evaluate the prognostic impact of preoperative CA-125 and to establish a prognostic index to identify patients in different risk categories. Data of 600 surgically staged patients with FIGO stage 1 EOC treated in eleven gynecological cancer centers in Australia, the USA and Europe were analyzed. Eligible patients include those with invasive EOC where a preoperative CA-125 was obtained and standard surgical staging performed. Overall survival (OS) was chosen as study endpoint. Preoperative CA-125 values were compared with other prognostic factors, and univariate and multivariate Cox models were calculated. Two hundred and one patients (33.5%) had preoperative CA-125 < or =30 U/ml and CA-125 levels < or =30 U/ml were associated with lower grade, sub-stage 1A and mucinous histologic cell type. Patients with elevated CA-125 levels were more likely to receive chemotherapy. OS probability was 95% and 85% for patients with pretreatment CA-125 < or =30 U/ml and >30 U/ml, respectively (p 0.003). Multivariate analysis confirmed preoperative serum CA-125 >30 U/ml (OR 2.7) and age at diagnosis >70 years (OR 2.6) as the only independent predictors for overall survival. Pretreatment of CA-125 < or =30 U/ml dominates over histologic cell type, sub-stage and grade to identify a subgroup of FIGO stage 1 patients with a genuinely good prognosis with extremely good survival and who could possibly be spared with adjuvant chemotherapy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 013225763

Download citation: RISBibTeXText

PMID: 17092548

DOI: 10.1016/j.ygyno.2006.09.021

Related references

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. International Journal of Gynecological Cancer 21(6): 1024-1031, 2012

Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. International Journal of Gynecological Cancer 21(2): 236-244, 2011

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. Obstetrics and Gynecology International 2015: 464123, 2015

Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology 140(2): 215-220, 2016

The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?. Gynecologic Oncology 142(2): 243-247, 2017

The prognostic significance of residual diseases, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecologic Oncology 56(2): 175-180, 1995

ADVANCED STAGE OF EPITHELIAL OVARIAN CANCER (II-IV FIGO STAGE). THE ROLE OF LYMPH NODE DISSECTION: IGCS-0019 Ovarian Cancer. International Journal of Gynecological Cancer 25 Suppl 1: 53, 2015

Advanced-Stage (Figo IiiIv) Epithelial Ovarian Cancer: Multivariate Analysis of Prognostic Factors in an Area without a Tertiary Referral Oncology Center. A Population-Based Study. Oncology Research and Treatment 22(5): 406-410, 1999

-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-. Geburtshilfe und Frauenheilkunde 56(2): 79-82, 1996

The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy. International Journal of Gynecological Cancer 28(3): 453-458, 2018

FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecologic Oncology 142(3): 597-607, 2017

Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. International Journal of Gynecological Cancer 13(5): 587-592, 2003

The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. International Journal of Gynecological Cancer 14(1): 51-56, 2004

A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. Gynecologic Oncology 126(3): 357-363, 2012

Treatment of ovarian cancer at FIGO stage III and IV--prognostic factors for patients receiving neoadjuvant chemotherapy. Nihon Sanka Fujinka Gakkai Zasshi 45(7): 665-672, 1993